Skip to main
  1. Stocks
  2. Teva Pharmaceutical
  3. Forecast
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is attractive because it is successfully shifting from a generics-heavy model toward a higher-margin branded and innovative portfolio, with 3Q26 revenue of $4.395B, non-GAAP EPS of $0.86, and gross margin rising to 55.5% from 51.4% a year earlier. Its core franchises are showing durable momentum, as Austedo, Ajovy, and Uzedy are either growing or stabilizing, while biosimilars are strengthening replenishment and management expects adjusted EBITDA of $4.23B to $4.43B in FY26. The outlook is further supported by a deep immunology and neuroscience pipeline, including Weltruza and ecopipam, which should extend growth into 2028 and improve operating leverage as R&D spending and commercial investment translate into future launches.

Bears say

Teva Pharmaceutical Indus is viewed negatively because its core growth drivers appear fragile: AUSTEDO sales must exceed guidance, maintain share through 2029, and avoid earlier generic erosion, while the Olanzapine LAI launch depends on a favorable PDSS-free label and strong uptake. Its innovation thesis also looks exposed, since duvakitug must succeed in Phase 3 against Merck or Roche, and the company still needs to double biosimilar revenue by 2027 while reversing generic weakness after the Revlimid headwind. Beyond operating risk, material opioid, price-fixing, and environmental contingencies could pressure cash flow and de-levering, making the overall earnings and margin profile less dependable.

Teva Pharmaceutical (TEVA) has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction

Get the latest Teva Pharmaceutical (TEVA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Teva Pharmaceutical (TEVA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 14 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction

Get the latest Teva Pharmaceutical (TEVA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Teva Pharmaceutical (TEVA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TEVA stock data and trends